<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986218</url>
  </required_header>
  <id_info>
    <org_study_id>CA002-001</org_study_id>
    <nct_id>NCT01986218</nct_id>
  </id_info>
  <brief_title>Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and effectiveness of daily doses&#xD;
      of BMS-986115 in subjects with advanced solid tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    (Non-safety reason, business objectives have changed)&#xD;
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple daily doses of BMS-986115</measure>
    <time_frame>Up to 30 days after the last dose of study medication (approximately 18 months)</time_frame>
    <description>Measured by the frequency of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, Grade 3 or 4 AEs, deaths, laboratory abnormalities and clinically relevant electrocardiogram (ECG) changes from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma half-life (T-HALF) of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of BMS-986115</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady-state (Vz/F) of BMS-986115</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986115</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(INF) to parent AUC(INF) after single dose and ratio of metabolite AUC(TAU) to parent AUC(TAU) at steady state, corrected for molecular weight (MR_AUC) of BMS-986115 and its active metabolite BMT-100948</measure>
    <time_frame>29 timepoints up to Cycle 3 Day 1 (approximately 32 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) changes in the expression of Notch pathway-related genes, including but not limited to Hes1 and Deltex1, as determined by standard molecular methods</measure>
    <time_frame>16 timepoints up to Cycle 2 Day 16 (approximately 20 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of BMS-986115 as measured by response evaluation criteria in solid tumors (RECIST)</measure>
    <time_frame>Screening (within 30 days prior to Day 1), Every 8 weeks, End of Treatment or 30-Day follow-up visits (approximately 18 months)</time_frame>
    <description>Assessed by:&#xD;
Tumor Response based on the Investigator's assessment using RECIST v1.1 [categorized as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD)]&#xD;
Best Overall Response (BOR), defined as the best tumor response recorded between the data of first dose and the last on-study tumor assessment (prior to any subsequent cancer therapy)&#xD;
Overall Response Rate, defined as the proportion of subjects with BOR responses of CR or PR&#xD;
Disease Control Rate, defined as the proportion of subjects with BOR responses of CR, PR or SD&#xD;
Progression-Free Survival (or PFS), defined as time from first dose to either progressive disease, initiation of subsequent off-study therapy, or death</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Various Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Dose Escalation (BMS-986115)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous daily dosing until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: Dose Expansion (BMS-986115)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous daily dosing until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Dose Escalation (BMS-986115)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice weekly dosing until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Dose Expansion (BMS-986115)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice weekly dosing until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986115</intervention_name>
    <arm_group_label>Arm A: Dose Escalation (BMS-986115)</arm_group_label>
    <arm_group_label>Arm A: Dose Expansion (BMS-986115)</arm_group_label>
    <arm_group_label>Arm B: Dose Escalation (BMS-986115)</arm_group_label>
    <arm_group_label>Arm B: Dose Expansion (BMS-986115)</arm_group_label>
    <other_name>BMS-986115 (Notch Inhibitor)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a histologically or cytologically confirmed diagnosis of solid tumors,&#xD;
             advanced or metastatic, refractory to or relapsed from standard therapies or for which&#xD;
             there is no known effective treatment&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score 0-1&#xD;
&#xD;
          -  Prior anti-cancer treatments are permitted (i.e., chemotherapy, radiotherapy,&#xD;
             hormonal, or immunotherapy)&#xD;
&#xD;
          -  At least 4 weeks must have elapsed from last dose of prior anti-cancer therapy and the&#xD;
             initiation of study therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known or suspected brain metastases, primary brain tumors, or brain as&#xD;
             the only site of disease&#xD;
&#xD;
          -  Evidence of uncontrolled, active infection, requiring systemic anti-bacterial,&#xD;
             anti-viral or anti-fungal therapy ≤ 7 days prior to administration of study medication&#xD;
&#xD;
          -  Current or recent (within 3 months of study drug administration) gastrointestinal&#xD;
             disease such as chronic or intermittent diarrhea, or disorders that increase the risk&#xD;
             of diarrhea, such as inflammatory bowel disease. Non-chronic conditions (e.g.&#xD;
             infectious diarrhea) that are completely resolved for at least 2 weeks prior to&#xD;
             starting study treatment are not exclusionary&#xD;
&#xD;
          -  Any major surgery or gastrointestinal disease that would interfere with administration&#xD;
             of oral medications&#xD;
&#xD;
          -  Conditions requiring chronic systemic glucocorticoid use, such as autoimmune disease&#xD;
             or severe asthma, excluding inhalation steroids for maintenance.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  History of medically significant thromboembolic events or bleeding diathesis within&#xD;
             the past 6 months&#xD;
&#xD;
          -  Inadequate bone marrow function (Absolute neutrophil count (ANC) &lt; 1,500 cells/mm3;&#xD;
             Platelet count &lt; 100,000 cells/mm3; Hemoglobin &lt; 9.0 g/dL)&#xD;
&#xD;
          -  Inadequate hepatic function (Total bilirubin &gt; 1.5 times the institutional upper limit&#xD;
             of normal (ULN) (except known Gilbert's syndrome); Alanine transaminase (ALT) or&#xD;
             aspartate transaminase (AST) &gt; 2.5 times the institutional ULN. ALT or AST up to 3&#xD;
             times the institutional ULN permitted if total bilirubin is normal&#xD;
&#xD;
          -  Uncontrolled (≥ Grade 2) hypertriglyceridemia (fasting triglycerides &gt; 300 mg/dL (3.42&#xD;
             mmol/L))&#xD;
&#xD;
          -  Inadequate renal function (Blood creatinine &gt; 1.5 times the institutional ULN)&#xD;
&#xD;
          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human&#xD;
             Immunodeficiency Virus (HIV) -1, -2 antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Usc/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

